We are joined by our Editor-in-Chief for European Oncology & Haematology, Axel S Merseburger, to discuss the recent results of the OLYMPUS trial, an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naïve or recurrent low-grade non-invasive UTUC with at least one measurable papillary tumor located above the ureteropelvic junction.
For further information on this trial, please follow the following links
1. Before the approval of mitomycin pyelocalyceal, how was low-grade upper tract urothelial cancer treated, and what are the treatment challenges associated with the upper urinary tract? (0:06)
2. How is the gel administered and what is the treatment regimen? (0:52)
3. Could you tell us about the aims, design and inclusion criteria of the OLYMPUS trial? (1:56)
4. What were the major efficacy and safety findings of this trial? (3:16)
5. What patients are most likely to benefit from this therapy and how might it impact the future of urothelial cancer? (4:10)
Axel S Merseburger has no conflicts of interest to declare in relation to this video.
Commissioned, edited and funded by Touch Medical Media
Published: 14 May 2020
Share this Video
Related Videos In Genitourinary Cancers
Axel Merseburger: International Men’s Day and EU Prostate Cancer Day and the Importance of Raising Awareness of Men’s Health and Well-being
Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), gives his thoughts on the importance of International Men’s Day and EU Prostate Cancer Day in raising awareness of men’s health and well-being. Question International Men’s Day and EU Prostate Cancer Day are both held in November. What is the importance of raising awareness of male […]
Axel S Merseburger, ESMO 2021: Highlights and Key Data in Advanced Prostate Cancer
touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice. Questions 1. What were the hottest topics and exciting new research from the ESMO […]
Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study
touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. Questions 1. What is the rationale for the combined use of cabozantinib and atezolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!